Adial Pharmaceuticals, Inc.
ADIL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001513525
In the last 90 days, Adial Pharmaceuticals, Inc. insiders filed 3 open-market purchases and 0 sales; 17 institutions reported holding it in 13F filings for Q2 2026, worth $334.6K in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Adial Pharmaceuticals, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +3 vs. Q3 2021
- Shares held
- 1.34M
- +52.4K (+4.1%) vs. Q3 2021
- Total value
- $3.61M
- −$1.90M (−34.5%) vs. Q3 2021
- New holders
- 5
- 3 more added
- Sold out
- 2
- 4 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ADIL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 17 | $334.6K |
| Q1 2026 | 15 | $63.8K |
| Q4 2025 | 24 | $778.4K |
| Q3 2025 | 17 | $214.8K |
| Q2 2025 | 17 | $70.8K |
| Q1 2025 | 14 | $152.7K |
| Q4 2024 | 15 | $298.1K |
| Q3 2024 | 12 | $195.9K |
| Q2 2024 | 16 | $328.0K |
| Q1 2024 | 16 | $236.2K |
| Q4 2023 | 17 | $495.3K |
| Q3 2023 | 11 | $164.2K |
| Q2 2023 | 21 | $488.2K |
| Q1 2023 | 23 | $876.9K |
| Q4 2022 | 23 | $359.2K |
| Q3 2022 | 28 | $692.1K |
| Q2 2022 | 26 | $2.27M |
| Q1 2022 | 23 | $6.38M |
| Q4 2021 | 24 | $3.61M |
| Q3 2021 | 21 | $5.50M |
| Q2 2021 | 19 | $3.15M |
| Q1 2021 | 20 | $1.95M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Adial Pharmaceuticals, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cornerstone Advisory, LLC | 25 | $0 | 0.00% | +25 | New |
| Morgan Stanley | 538 | $1.00K | 0.00% | −39,690−98.7% | Reduced |
| Wells Fargo & Company | 865 | $2.00K | 0.00% | 00.0% | Unchanged |
| Benjamin F. Edwards & Company, Inc. | 1,000 | $3.00K | 0.00% | 00.0% | Unchanged |
| High Net Worth Advisory Group LLC | 1,000 | $3.00K | 0.00% | +1,000 | New |
| UBS Group AG | 3,624 | $10.0K | 0.00% | −766−17.4% | Reduced |
| Group One Trading, L.P. | 6,200 | $17.0K | 0.00% | +6,200 | New |
| Advisor Group Holdings, Inc. | 8,321 | $22.0K | 0.00% | 00.0% | Unchanged |
| Charles Schwab Investment Management Inc | 11,609 | $32.0K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 12,192 | $33.0K | 0.00% | +12,192 | New |
| Rede Wealth, LLC | 15,200 | $41.0K | 0.02% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 19,526 | $53.0K | 0.00% | +19,526 | New |
| Millennium Management LLC | 20,746 | $56.0K | 0.00% | +3,697+21.7% | Added |
| Brown Advisory Inc | 26,040 | $70.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 29,299 | $79.0K | 0.00% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 31,410 | $85.0K | 0.00% | 00.0% | Unchanged |
| Private Advisor Group, LLC | 34,150 | $92.0K | 0.00% | −1,250−3.5% | Reduced |
| Commonwealth Equity Services, LLC | 36,461 | $98.0K | 0.00% | 00.0% | Unchanged |
| Oppenheimer & Co Inc | 38,500 | $104.0K | 0.00% | 00.0% | Unchanged |
| Raffa Wealth Management, LLC | 41,845 | $113.0K | 0.04% | 00.0% | Unchanged |
| State Street Corp | 50,154 | $135.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 129,327 | $349.0K | 0.00% | +33,250+34.6% | Added |
| BlackRock Inc. | 227,178 | $613.0K | 0.00% | +31,923+16.3% | Added |
| Vanguard Group Inc | 590,852 | $1.59M | 0.00% | −3,591−0.6% | Reduced |
| NorthRock Partners, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −95−100.0% | Sold out |